Independent research resourceFor laboratory research use only
bimagrumabexpert.

Research brief

Bimagrumab and semaglutide in the BELIEVE trial

Understand the BELIEVE phase 2 study design and how to read combination-therapy research without confusing clinical evidence with reagent specifications.

Back to research news
Phase 2 · BELIEVEBrief reviewed 2026-10-08
Blue-gloved researcher using a pipette to transfer laboratory cell culture material.
Illustrative photograph · NIAID / Unsplash

Start with the design

BELIEVE randomised 507 adults across nine groups. The study evaluated bimagrumab, semaglutide and their combinations over a 48-week primary treatment period. Results were published in Nature Medicine in March 2026.

Why multiple groups matter

A combination study asks several questions at once. When comparing outcomes, identify the relevant group, comparator, endpoint and time point. A headline about a combination should not be treated as a result for either component used alone.

Keep measurements distinct

Body weight, fat mass and lean mass describe different things. Reading the outcome definition first helps prevent one measure from standing in for another. The analysis population and missing-data approach also belong in the interpretation.

Separate clinical research from procurement

A published trial is evidence about its own research question. It does not certify a product sold by an unrelated supplier. A procurement review still needs batch identity, analytical methods, application requirements and the relevant documentation.

Research brief by Bimagrumab Expert. No clinical advice or product endorsement is intended. Review funding disclosures and updates in the original source.

Read the original source

Nature Medicine · BELIEVE, 2026

To flag a correction, use the contact form.